This ones a heck of a specualive investment but it seems that the institutions are willing to stomp up the cash to back it in the long term.

Heres the latest news from Killik stocbrokers on the company..........

MEDICAL MARKETING Joint Venture

We recently highlighted Medical Marketing (MMG) as worthy of attention. The company, in which I have a personal share holding, has this morning announced the formation of a joint venture, Genvax, to develop a novel DNA vaccine platform technology.

Human trials have been underway since 2001 in areas such as Lymphoma and Myeloma but the technology has broad applications in cancer, viral and bacterial infections (hence the term platform). The technology works on boosting the immune system by teaching it to identify hard to recognise cancer proteins as foreign and destroy them. Early results from the 25 patient trial in lymphoma are encouraging and evaluation of the result is expected by March 2005. Successful results should mean big pharmaceutical groups will start to take financial and commercial interests around that time.

This looks to be the first of a series of announcements due from Medical Marketing as it has a range of predominantly cancer trials moving into the clinical stage. (news flow could push the price higher)

The stock has made good progress in recent sessions up to the mid-80p level where the company is valued at just under 40 million. ENDS.

Please DYOR

cheers GF.

I have been watching dag for sometime and am waiting for a suitable buy opportunity, i will take a look at cra..... thanks

rob do not wait much longer with DAG.!

More news out on the Mike walters board this evening. Anyone know briefly what he was saying??????...........................


Patently Obvious
13/4/2005

More about Medical Marketing and the issues it raises.
[Read more]

cheers GF.

or if it was + or - would help!
It's been a vey interesting couple of weeks anyway,opened my eyes up to other factors ie.shorters and the big effect they can have on a sp.Hopefully things might change in the next couple of years!

Bound to be positive coming from Mike, well I think so.

And heres another positive buy from British Bulls.

http://www.britishbulls.com/StockPage.asp?CompanyTicker=MMG&MarketTicker=NON-CYCLICALS&Typ=S

cheers GF.

http://www.britishbulls.com/StockPage.asp?CompanyTicker=MMG&MarketTicker=NON-CYCLICALS&Typ=S

Have recently been watching this one closely after missing the boat on the initial rise. Have been affected by shorters on more than one occasion and have often wondered how the likes of EK cover themselves before announcing manipulative short positions.
Hopefully get in below 200p tommorrow.
Tau.

Got this from the other place.

surfnturf - 14 Apr'05 - 11:26 - 4919 of 4922


Positive note out from Insinger's in their Daily UK morning briefing under the title MMG,patent portfolio strentghened, highly respected analyst (unlike GW!) re-iterating that it is a buy with a DCF price of 275p against a morning's share price of 177p generating some 55% upside potentials.Just a brief note expect a full detailed comprehensive note from Insinger's next week.

The market does not understand the full implications of the value of the DNA vaccine patents and the shorters/daytraders don't care.They will as soon as the the SP moves substantially higher on very positive news!!

I think that the shorters will be crying in their beer soon, so don't worry MMG investors lots of good news on the way.

MS

Good post MS, Appreciate your research on this.

Yea nice one.

Yes great to see the broker out with a new buy and confirmation that Peel Hunt and its broker were talking clap trap.

cheers GF.

Going nicely at the end of day.

cheers Gf.

When I get the new note I will forward it on for the Evil one to have a look at.

cheers GF.

Comme on Guys lets blast Evil out.

cheers GF.

Good news this morning an excelent appointment to the board...........

Medical Marketing Int'l Group PLC
15 April 2005


For Immediate Release 15 April 2005

MEDICAL MARKETING INTERNATIONAL GROUP PLC

MMI APPOINTS MEDICAL DIRECTOR DESIGNATE

Medical Marketing International Group plc (MMI) (AIM: MMG), the Cambridge,
UK-based pharmaceutical development company focussed on the development of
potential therapies for cancer and infectious diseases, announces that it has
appointed Dr James Brenton (40) as Medical Advisor with immediate effect. This
appointment is part-time and Dr Brenton will continue with his medical career.
It is intended that Dr Brenton will join the MMI Board on or before the next AGM
as Medical Director.

Dr Brenton is a Cancer Research UK Senior Clinical Research Fellow and Honorary
Consultant in Medical Oncology at the University of Cambridge. Dr Brenton's
current research involves clinical trials using platinum-based drugs in cancer
patients. He gained his MB BS in 1988 at University College London Medical
School. James gained his Membership of the Royal College of Physicians in 1991.
In 2001 he was awarded a PhD from the University of Cambridge and gained his
Certificate of Completion of Specialist Training in Medical Oncology in the same
year.

Dr Brenton is a member of the Association of Cancer Physicians, European Society
for Medical Oncology and British Association for Cancer Research. He is also a
member of several national committees for cancer research.

Commenting on this appointment, David Best, Chairman of MMI Group said 'This is
a very exciting time for MMI. There are already four ongoing cancer vaccine
trials with our Genvax technology, and further clinical trials on cancer
vaccines are expected this year. Together with the planned clinical trials on
ruthenium and our pineapple proteases, we may have ten or more cancer clinical
trials ongoing this year. The experience James brings to the team, especially
his expertise in the use of platinum-based drugs in cancer therapy trials, is
both timely and very useful. We all wish James every success at MMI and
continuing success in his existing positions.'

Dr James Brenton said: 'Cancer is an area of medicine where there is still much
to be done. MMI's portfolio of potential cancer therapies is now at an exciting
stage of development and I look forward to adding my expertise in this area to
the developmental and commercial expertise already at MMI.'

For further information, please contact:

David Best - Chairman
MMI Group Tel: +44 (0)1223 477677

www.mmigroup.co.uk


cheers GF.

This is just getting better. EK want's to be very careful, but as he's a shrewed old boy I wouldn't be supprised to see him reverse his position and go long.

MS

Apparently there is a presentation by MMI at Buchannons offices on the 26th of the month where about 60 brokers/interested parties will attend to hear the latest from Ruthenium and Genvax..

Good news Mitzy, looks like we may have news earlier than we thought.

cheers GF.

You can have mine for 10 and I'll throw in the MIL.

MS

Starting to move back in a little on buys.

cheers GF. PS, oh what a rotten day.